BMO Capital Markets Downgrades Eli Lilly and Co (LLY) to Underperform
Other analysts also recently issued research reports about the company. Zacks Investment Research raised Eli Lilly and from a "hold" rating to a "buy" rating and set a $94.00 target price on the stock in a research note on Tuesday, April 4th.
Start the conversation, or Read more at AmericanBankingNews.com.